Search | IOVS | ARVO Journals

Showing 1 – 17 of 17

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina October 2018

How to Ward Off Retinal Toxicity of Perfluorooctane and Other Perfluorocarbon Liquids?

PDF

Dirk-Henning Menz; Nicolas Feltgen; Helge Menz; Bernd-Kristof Müller; Thorsten Lechner; Joachim Dresp; Hans Hoerauf
TAGS: patent foramen ovale, fluorides, fluorocarbons, patients' rooms, safety, cytotoxicity, retinal toxicity, liquids, perfluorooctane
Invest. Ophthalmol. Vis. Sci.. 2018; 59(12):4841-4846. doi: 10.1167/iovs.18-24698

ARVO Annual Meeting Abstract July 2018

Comparison of different approaches for quantification of retinal ischemia in OCTA

Peer Lauermann; Christian van Oterendorp; Nicolas Feltgen; Hans Hoerauf; Sebastian Bemme

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2884. doi:

ARVO Annual Meeting Abstract July 2018

Intracellular uptake of Bevacizumab in human Tenon-Fibroblasts

Florian Hasan; Christian van Oterendorp; Charlotte Fischer; Nicolas Feltgen; Hans Hoerauf

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4726. doi:

ARVO Annual Meeting Abstract June 2017

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

David M Brown; Yuichiro Ogura; Francesco Boscia; Frank G Holz; Jean-Francois Korobelnik; Jeffrey Heier; Kay D Rittenhouse; Friedrich Asmus; Christiane Ahlers; Florian Hiemeyer; Chengxing Lu; Robert Vitti; Namrata Saroj; Nicolas Feltgen

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1559. doi:

ARVO Annual Meeting Abstract June 2017

Real-life effectiveness of Ranibizumab in RVO patients in a prospective, non-interventional trial over 12 months (OCEAN study)

Josep Callizo; Thomas Bertelmann; Jessica Voegeler; Steffen Schmitz-Valckenberg; Georg Spital; Nicolas Feltgen; Sandra Liakopoulos; Focke Ziemssen

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3674. doi:

ARVO Annual Meeting Abstract September 2016

Safety and efficacy of ranibizumab 0.5 mg vs dexamethasone 0.7 mg intravitreal implant in patients with branch or central retinal vein occlusion: long-term results of the COMRADE-Extension study

Nicolas Feltgen; Thomas Bertelmann

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

The antiproliferative effect of bevacizumab on human tenon fibroblasts is presumably not through VEGF inhibition.

Charlotte Fischer; Viktoria Mans; Nicolas Feltgen; Hans Hoerauf; Christian van Oterendorp

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2931. doi:

ARVO Annual Meeting Abstract September 2016

Is micropulse diode laser photocoagulation effective in treating recalcitrant chronic central serous chorioretinopathy?

Nina-Antonia Striebe; Mohammed Khattab; Christian van Oterendorp; Josep Callizo; Hans Hoerauf; Nicolas Feltgen

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5346. doi:

ARVO Annual Meeting Abstract September 2016

Intravenous fibrinolysis in acute non-arteritic central retinal artery occlusion - revisited

Martin Stephan Spitzer; Sven Poli; Florian Haertig; Nicolas Feltgen; Max Schultheiss

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5352. doi:

ARVO Annual Meeting Abstract September 2016

Atrial fibrillation and carotid artery disease in patients with retinal artery occlusion, retinal vein occlusion and anterior ischemic optic neuropathy

Josep Callizo; Nicolas Feltgen; Rolf Wachter

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2050. doi:

ARVO Annual Meeting Abstract June 2015

Efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg in central retinal vein occlusion: 6-month results of the COMRADE-C study

Nicolas Feltgen; on behalf of the COMRADE-C study group

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5804. doi:

ARVO Annual Meeting Abstract June 2015

Effect of Baseline Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) on Treatment Outcomes With Intravitreal Aflibercept Injection (IAI) or Macular Laser Photocoagulation in Diabetic Macular Edema (DME)

Yuichiro Ogura; Nicolas Feltgen; Jean-Francois Korobelnik; Edoardo Midena; Todd A Katz; Claudia Teukmantel; Carola Metzig; Oliver Zeitz; VIVID-DME and VISTA-DME study investigators

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1748. doi:

ARVO Annual Meeting Abstract April 2014

Predictors of Prognosis and Treatment Outcome in Central Retinal Artery Occlusion: results of the randomized multicenter EAGLE trial

Bernd Junker; Stefanie Pantenburg; Josep Callizo; Claudia Schmoor; Martin Schumacher; Nicolas Feltgen; Amelie Pielen; EAGLE Study Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):684. doi:

ARVO Annual Meeting Abstract April 2014

Efficacy of intravitreal ranibizumab given bimonthly versus PRN in patients with neovascular age-related macular degeneration: 1 year results of a prospective, randomized clinical trial.

Nicolas Feltgen; Sebastian Pfeiffer; Anke Goerlitz; Heike Hennig; Mirko Bretag; Henrike Neunhöffer; Elisabeth Wetzel; Christoph Krüger; Josep Callizo; Hans Hoerauf; RABIMO Study group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3930. doi:

ARVO Annual Meeting Abstract March 2012

Dexamethasone Intravitreal Implant (Ozurdex®) In Patients With Macular Edema Due To Retinal Vein Occlusion

Mathias M. Maier; Thomas Groneberg; Nikolaus Feucht; Carsten H. Meyer; Georg Spital; Joachim Wachtlin; Lars O. Hattenbach; Nicolas Feltgen; Chris P. Lohmann

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):920. doi:

ARVO Annual Meeting Abstract April 2011

Vitreal Erythropoietin Is Elevated Following Retinal Vein Occlusion Independent Of Serum Levels

Anima D. Buehler; Bernd Junker; Armin Buchwald; Gottfried Martin; Lutz L. Hansen; Hansjuergen T. Agostini; Nicolas Feltgen; Jing Chen; Lois E. Smith; Andreas Stahl

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5628. doi:

Visual Psychophysics and Physiological Optics March 2006

Visual Acuities “Hand Motion” and “Counting Fingers” Can Be Quantified with the Freiburg Visual Acuity Test

PDF

Kilian Schulze-Bonsel; Nicolas Feltgen; Hermann Burau; Lutz Hansen; Michael Bach
TAGS: motion, visual acuity, fingers, hand, etdrs visual acuity chart, visual acuity testing
Invest. Ophthalmol. Vis. Sci.. 2006; 47(3):1236-1240. doi: 10.1167/iovs.05-0981

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

How to Ward Off Retinal Toxicity of Perfluorooctane and Other Perfluorocarbon Liquids?

Comparison of different approaches for quantification of retinal ischemia in OCTA

Intracellular uptake of Bevacizumab in human Tenon-Fibroblasts

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

Real-life effectiveness of Ranibizumab in RVO patients in a prospective, non-interventional trial over 12 months (OCEAN study)

Safety and efficacy of ranibizumab 0.5 mg vs dexamethasone 0.7 mg intravitreal implant in patients with branch or central retinal vein occlusion: long-term results of the COMRADE-Extension study

The antiproliferative effect of bevacizumab on human tenon fibroblasts is presumably not through VEGF inhibition.

Is micropulse diode laser photocoagulation effective in treating recalcitrant chronic central serous chorioretinopathy?

Intravenous fibrinolysis in acute non-arteritic central retinal artery occlusion - revisited

Atrial fibrillation and carotid artery disease in patients with retinal artery occlusion, retinal vein occlusion and anterior ischemic optic neuropathy

Efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg in central retinal vein occlusion: 6-month results of the COMRADE-C study

Effect of Baseline Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) on Treatment Outcomes With Intravitreal Aflibercept Injection (IAI) or Macular Laser Photocoagulation in Diabetic Macular Edema (DME)

Predictors of Prognosis and Treatment Outcome in Central Retinal Artery Occlusion: results of the randomized multicenter EAGLE trial

Efficacy of intravitreal ranibizumab given bimonthly versus PRN in patients with neovascular age-related macular degeneration: 1 year results of a prospective, randomized clinical trial.

Dexamethasone Intravitreal Implant (Ozurdex®) In Patients With Macular Edema Due To Retinal Vein Occlusion

Vitreal Erythropoietin Is Elevated Following Retinal Vein Occlusion Independent Of Serum Levels

Visual Acuities “Hand Motion” and “Counting Fingers” Can Be Quantified with the Freiburg Visual Acuity Test

To View More...

You must be signed into an individual account to use this feature.